ADV-TK Improves Outcome of Recurrent High-Grade Glioma (HGG-01)
Adenovirus-Mediated Delivery of Herpes Simplex Virus Thymidine Kinase Administration Improves Outcome of Recurrent High-Grade Glioma
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100069
- Beijing Youan Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Histologically confirmed WHO grades 3 to 4 malignant glioma
- Diagnosed recurrence or progression by clinical or radiological evidence
- Fit for intraarterial infusion and intravenous chemotherapy
- Adequate hepatic, renal, and hematologic function.
- Legal age ≥18 years
- Life expectancy ≥12 weeks
- Eastern Cooperative Oncology Group performance (ECOG) ≥2
- Chemotherapy completion ≥4 weeks prior and recovery from drug induced toxicities.
Exclusion Criteria:
- Active pregnancy
- Prior gene therapy
- Second primary tumor
- Gravidity, lactation, hypersensitivity to antiviral drugs, immunologic deficit, active uncontrolled infections
- Requiring treatment with warfarin or any other anticoagulants
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: ADV-TK/GCV
ADV-TK was administered via intraarterial cerebral infusion.
Systemic GCV therapy was delivered at a dose of 5mg/kg intravenous, every 12 h at 36 hours after ADV-TK therapy.
|
gene therapy
|
|
Active Comparator: Control group
Patients received surgery or systemic chemotherapy or palliative care.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
The primary end point was 6-month progression-free survival rate (PFS-6)
Time Frame: 6 months
|
6 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
overall survival (OS)
Time Frame: 3 years
|
3 years
|
|
|
progression-free survival (PFS)
Time Frame: 3 years
|
3 years
|
|
|
safety
Time Frame: 1. at the time during treatments; 2. at 6-month; 3. at the end of 1-year following-up; 4. at the end of 2-year following up; 5. at the time the patient censored.
|
1. at the time during treatments; 2. at 6-month; 3. at the end of 1-year following-up; 4. at the end of 2-year following up; 5. at the time the patient censored.
|
|
|
clinical benefit
Time Frame: at the end of 2nd ADK-TK/GCV therapy
|
the rate of complete response, plus partial response, plus stable disease
|
at the end of 2nd ADK-TK/GCV therapy
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2009HGG-01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.